Holista Locks in $1.6M JV to Fund Collie Collagen Plant With Path to 75% Stake

Holista Colltech secures binding JV to fund Collie collagen facility

Holista Colltech has executed a binding Joint Venture Agreement with Hong Kong-listed Swang Chai Chuan Limited (HKEX: 2321) for an ovine nano-collagen production facility in Collie, Western Australia. The JV will operate through Ovicoll Pty Ltd with initial 50:50 ownership, funded by SCC’s contribution of RM5,000,000 (approximately A$1.6 million) to cover commissioning and working capital. The agreement contains no material conditions precedent, marking a commercialisation milestone for Holista’s collagen technology whilst removing funding risk from the company’s balance sheet.

The partnership provides Holista with external capital validation and establishes a platform to produce high-value nano-collagen products for nutraceutical, food, cosmetic, and biomedical applications. SCC’s involvement brings regional distribution capabilities and market access, particularly across Asian markets where consumer demand for premium collagen products continues to expand.

What is ovine nano-collagen?

Ovine collagen is derived from sheep, positioning it as a disease-free alternative to bovine sources which carry higher contamination risks. The nano-processing technique reduces collagen to nano-scale particles, enhancing bioavailability and absorption rates compared to conventional collagen products.

This processing advantage makes ovine nano-collagen suitable for premium applications across nutraceuticals, food ingredients, cosmetics, and biomedical products. Western Australia’s established sheep industry provides a reliable supply of high-quality raw material, supporting consistent production standards at the Collie facility.

The technology occupies a differentiated market segment above commodity collagen producers, targeting consumers and manufacturers willing to pay premiums for superior absorption characteristics and verified source integrity.

JV commercial terms and Holista’s path to 75% ownership

Under the agreement, SCC’s RM5,000,000 capital contribution funds the facility’s commissioning and initial operations. Holista will make payments equivalent to 3% per annum on this amount for two years, providing SCC with a defined return whilst the facility ramps production.

Critically, Holista retains a contractual option to increase ownership to 75%, exercisable between the second and fifth anniversaries of SCC’s initial contribution. The option’s valuation will follow a pre-agreed methodology, providing clarity on future acquisition pricing.

This structure allows Holista to demonstrate commercial traction before committing additional capital to majority ownership. Once the facility establishes revenue generation and validates market demand, the company can consolidate control and economics through the ownership option.

For investors, the pathway to 75% ownership represents a material upside mechanism if the JV performs. The company avoids upfront dilution or balance sheet strain whilst maintaining the ability to capture majority value creation as production scales.

Governance, IP ownership and royalty structure

Holista will manage day-to-day JV operations, providing operational control despite equal initial ownership. The Ovicoll Pty Ltd board will comprise equal representation from both partners, balancing strategic oversight with Holista’s management authority.

Holista retains ownership of all pre-existing and newly developed intellectual property, with the JV receiving a licence to use the technology. This structure protects the company’s core technology assets regardless of JV performance whilst enabling commercial deployment through Ovicoll.

The JV will pay Holista a royalty of 8% of gross sales, capped at 20% of profit before tax. This dual-tier structure provides base revenue participation from all sales whilst limiting royalty impact on profitability during early production phases when margins may compress.

Personal guarantee disclosure

Dr Rajen Manicka, a substantial shareholder, has provided a personal guarantee to SCC for certain JV financial obligations. The guarantee is secured by his Holista shares and provided in his personal capacity, not as a Company obligation.

For investors, Holista’s retention of IP ownership decouples the company’s core technology value from JV execution risk. Even if Ovicoll underperforms, Holista maintains the ability to licence or deploy its collagen technology through alternative structures. The 8% gross sales royalty generates revenue from production scale rather than profitability alone, providing earlier cash flow participation.

SCC partnership and market access

Swang Chai Chuan Limited (HKEX: 2321) brings established distribution networks and consumer market experience to the partnership. The Hong Kong-listed company is expected to support market development activities, leveraging its regional presence to facilitate product commercialisation.

SCC’s involvement provides Holista with access to Asian distribution channels without requiring the company to build these capabilities independently. This reduces go-to-market risk and accelerates potential revenue generation, particularly in markets where collagen products command premium pricing.

The partnership structure aligns incentives for both parties. SCC’s capital contribution and guaranteed return depend on successful facility commissioning, whilst Holista’s ownership option creates upside participation if the JV demonstrates commercial traction.

For investors, SCC’s regional network addresses a critical commercialisation gap. Establishing distribution channels in Asian markets typically requires years of relationship development and market navigation. The JV structure provides immediate access through SCC’s established presence, potentially compressing the timeline to revenue generation.

Strategic positioning and next steps

The Collie facility positions Holista to serve four target market segments requiring different product specifications and quality standards:

• Nutraceutical applications – dietary supplements and wellness products
• Food ingredients – functional additives for processed foods and beverages
• Cosmetic formulations – anti-ageing and skin health products
• Biomedical products – medical-grade collagen for wound healing and tissue engineering

This multi-market approach provides revenue diversification whilst leveraging the same core production platform. The facility can adjust product specifications to serve different segments without requiring separate manufacturing lines.

The JV advances Holista’s Ovine Collagen division toward commercial production, potentially unlocking a new revenue stream alongside existing operations. The company operates across four core business divisions:

• Dietary Supplements
• Healthy Food Ingredients
• Ovine Collagen
• Infection Control Solutions

Holista has stated it will provide updates on development milestones and commissioning timing in due course. Investors should monitor announcements regarding facility construction progress, initial production runs, and customer qualification processes as indicators of commercialisation momentum.

The binding JV Agreement removes funding uncertainty for the Collie facility whilst preserving Holista’s option to increase ownership once commercial validation occurs. For a company with A$1.6 million in external capital now committed to production infrastructure, the structure balances execution risk with upside participation through the 75% ownership pathway available from Year 2 onwards.

Don’t Miss the Next Consumer Breakthrough

Join 20,000+ investors getting FREE breaking ASX news delivered within minutes of release, complete with in-depth analysis. Big News Blast provides real-time alerts from tech, healthcare, finance, consumer, and manufacturing sectors the moment market-moving announcements hit the ASX. Click the “Free Alerts” button to stay ahead.